By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered ...

Hudson has previously said he was looking for M&A deals this year to shore up its already-strong position in immunology, ...

Merck’s combo of KEYTRUDA and Trodelvy reduces disease progression or death risk by 35% in tough-to-treat breast cancer.

Gilead has already announced intentions to bring the data, which demonstrated a 35 percent reduction in risk of progression ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

A new clinical trial has shown that combining Gilead Sciences, Inc. (NASDAQ:GILD)’s Trodelvy with Merck & Co., Inc. (NYSE:MRK ...

As Mongolia's parliament prepares to vote on Monday on whether the country's coalition government should remain in office, new economic analysis warns that the demise of the government could see the ...

Sara M. Tolaney, MD, MPH, shares new data from the ASCENT-04 trial of sacituzumab govitecan and pembrolizumab in triple-negative breast cancer.

(RTTNews) - Merck & Co Inc. (MRK) announced that KEYTRUDA (pembrolizumab) plus Trodelvy (sacituzumab govitecan-hziy) reduced the risk of disease progression or death by 35% compared to KEYTRUDA plus c ...

Keytruda shows a 35% reduced risk of disease progression or death against a type of aggressive breast cancer. Read more here.